COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia.
作者信息
Sookaromdee Pathum, Wiwanitkit Viroj
机构信息
Private Academic Consultant, Bangkok, Thailand.
Department of Biological Science, Joseph Ayobabalola University, Ikeji, Arakeji, Nigeria; Department of Community Medicine, Dr D. Y. Patil University, Pune, India.
出版信息
Transplant Cell Ther. 2022 Aug;28(8):515. doi: 10.1016/j.jtct.2022.05.024. Epub 2022 May 19.
Abstract
摘要
相似文献
1
COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia.
Transplant Cell Ther. 2022 Aug;28(8):515. doi: 10.1016/j.jtct.2022.05.024. Epub 2022 May 19.
2
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Blood Adv. 2022 Jan 25;6(2):686-689. doi: 10.1182/bloodadvances.2021006112.
3
Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Eur J Haematol. 2016 Apr;96(4):389-96. doi: 10.1111/ejh.12602. Epub 2015 Jul 3.
4
Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients.
Blood. 2022 Jul 14;140(2):156-160. doi: 10.1182/blood.2022016166.
5
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.
6
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
J Clin Oncol. 2020 Nov 10;38(32):3805-3815. doi: 10.1200/JCO.20.01467. Epub 2020 Oct 6.
7
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.
8
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
9
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.
10
B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?
Sci Transl Med. 2022 Jun 22;14(650):eabn3353. doi: 10.1126/scitranslmed.abn3353.
Zotero 插件